All In Biotech

Drug Trial Radar · NCT06000657

Efficacy and Safety of Switching to Vemliver From Entecavir in Chronic Hepatitis B Patients Previously Treated With Entecavir

Efficacy and Safety of Switching to Vemliver (Tenofovir Alafenamide) From Entecavir in Chronic Hepatitis B: A Multi-Center, Phase IV, Open-Label, Randomized, Active-Controlled, Non-Inferiority Trial.

Last checked: Nov 20, 2026Latest source record: Mar 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 196 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

196

Actual

Start

Aug 28, 2023

Primary completion

Feb 3, 2025

Study completion Feb 3, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Enroll patients who are pre-treated with Entecavir at least 24 weeks and confirmed HBV antiviral (HBV DNA \<69 IU/mL) effects. Subjects are given one test drug or comparator once a day for 48 weeks according to the results of random assignments, and their HBV antiviral inhibitory effect and safety are evaluated at 24 and 48 weeks visits.

Conditions

  • Hepatitis B, Chronic

Interventions

  • Vemliver tabletDrug

    Chronic Hepatitis B Patients Who Pretreated with Entecavir switching to Vemliver tab (Tenofovir Alafenamide Hemitartrate)

  • Baracross TabletDrug

    Chronic Hepatitis B Patients Who Pretreated with Entecavir continuting treatement with Baracross Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HBV viral suppression rateTime frame: 48 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.